The agreement gives Novo exclusive global rights to apply PharmaShell to as many as five peptide-drug programs. Monthly and quarterly injections are targets, not approved products, and most of the headline value remains contingent on development and sales.
A programmable trapped-ion device reproduced a simplified model of particle-pair formation and tracked the process in space and time. The experiment is a physics benchmark—not yet a quantum advantage demonstration.
The $30 million spacecraft could not capture and raise the aging observatory, but its 85-day flight produced unusually candid evidence about the promise—and unforgiving engineering—of commercial satellite servicing.
A population-scale atlas of the human prefrontal cortex links cell-specific gene activity across Alzheimer’s, Parkinson’s, schizophrenia and five other conditions—but it is a research map, not a diagnostic test or treatment.
The agreement, effective April 1, 2027, preserves Apple's access to Qualcomm's global patent portfolio even as Apple reduces its reliance on Qualcomm modem chips. Duration and financial terms were not disclosed.
Anthropic says a coordinated group of Claude agents found a reverse-transcriptase system with CRISPR-like repeat arrays, then human scientists confirmed its molecular components in the lab. Its biological function remains unknown.
The $1,299.99 device separates its displays and sensors from a wired compute puck, cutting face weight while preserving full VR. It is scheduled to go on sale in spring 2027.
A localized version of OpenEvidence will be offered free to clinicians across roughly 100 lower-income countries, extending medical decision support while leaving safety, validation and real-world outcomes to be proven locally.
The startup says compatible Bluetooth Low Energy products can now send location and sensor data through its space-and-ground network without a dedicated satellite modem, moving a striking connectivity idea into commercial availability.